3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase NA
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia
2
Breast Neoplasms
2
Vomiting
1
Uterine Cervical Neoplasms
1
Trigger Finger Disorder
1
Sarcoma, Alveolar Soft Part
1
Renal Insufficiency
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Pain
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nausea
1
Mucositis
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Mast-Cell
1
Leukemia, Hairy Cell
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
Acetaminophen
×
Clear all
NCT00712712
2025-08-29
MEDOR
Institut Bergonié
Phase 2
Completed
78 enrolled
28 charts